amitriptyline has been researched along with s 1033 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gadhe, CG; Jo, S; Kim, H; Kim, JE; Kim, M; Kim, S; Kim, WR; Ko, HS; Kweon, SH; Kwon, SH; Lee, J; Lee, S; Ma, SX; Oh, Y; Park, AY; Park, JS; Seo, BA | 1 |
1 review(s) available for amitriptyline and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amitriptyline and s 1033
| Article | Year |
|---|---|
A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease.
Topics: Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Proto-Oncogene Proteins c-abl; Structure-Activity Relationship | 2021 |